




The relative strengths and weaknesses of Enanta Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Enanta Pharmaceuticals INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 172% points. The greatest weakness of Enanta Pharmaceuticals INC is the variable Intangible Assets, reducing the Economic Capital Ratio by 1.3% points.

The company's Economic Capital Ratio, given in the ranking table, is 443%, being 201% points above the market average of 243%.

Input Variable	Value in 1000 USD
Assets, Current	104,713
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	4,526
Liabilities, Non-Current	359
Other Assets	11,139
Other Compr. Net Income	-12
Other Expenses	0
Other Liabilities	1,620
Other Net Income	598
Other Revenues	32,053
Property and Equipment	1,121
Research and Development	16,841
Selling, General and Administrative Expense	6,183

Output Variable	Value in 1000 USD
Assets	116,973
Liabilities	6,505
Expenses	23,024
Revenues	32,053
Stockholders Equity	110,468
Net Income	9,627
Comprehensive Net Income	9,621
BaseVar	89,582
ECR before Limited Liability	406%
Economic Capital Ratio	443%